Skip to content
The Policy VaultThe Policy Vault

Nexavar (sorafenib)Medica

Differentiated thyroid carcinoma (radioactive iodine refractory)

Initial criteria

  • age ≥ 18 years
  • differentiated thyroid carcinoma (papillary, follicular, or Hürthle cell)
  • disease refractory to radioactive iodine therapy

Approval duration

1 year